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ABSTRACT 
Since 1974, when Moll and Wright first classified the seronegative spondyloarthropathies on 
the basis of their lack of positivity for rheumatoid factor, little insight has been made into the role 
played by the adaptive immune system within these diseases. We know in other rheumatic diseases 
like rheumatoid arthritis, systemic lupus erythematosus, myositis, and scleroderma that not only are 
autoantibodies present, but that in each of these diseases multiple specificities have been observed. 
Additionally, in these rheumatic diseases there is a striking correlation between autoantibody 
specificity and clinical phenotype. This observance highlights the significant force that B cell 
mediated autoantibodies play at the molecular level in impacting a patient’s course of disease. New 
technological advancements have led to large scale screens aimed at identifying clinically relevant 
autoantibodies. In the spondyloarthropathies, a number of groups have claimed to identify a limited 
set of autoantigens. Here, in chapters 1 and 2, we used the most advanced of these screens by 
interrogating a human protein array (HuProt array) consisting of ~17,000 recombinantly expressed 
human proteins with patient serum from psoriatic arthritis and ankylosing spondylitis. This high 
throughput, exploratory approach led to the identification of TBX20 and IFN-α as autoantigens in a 
cohort of psoriatic arthritis patients. 
In chapters 3 and 4, we lay the groundwork for the development of a scQa-1b; β2m -/- 
mouse model to explore Qa-1 dependent T cell development and peripheral CD8+ T cell phenotype. 
Predominantly, our knowledge of T cell development is centered on the role played by classical MHC 
Ia molecules. However, far less is known about nonclassical MHC Ib development. Previous work by 
others, has led to insights suggesting MHC Ib mediated selection can lead to peripheral CD8+ T cells 
with an “innate-like” phenotype, while other groups have suggested the presence of a Qa-1 
restricted CD8+ regulatory T cell lineage. Using this mouse model we aimed to provide additional 
support and insights into the presence of these T cell subsets. However, as we will discuss in detail 
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while this transgene did express in a number of cell lines, our mouse model failed to demonstrate in 
vivo scQa-1b expression.  
During this process we also developed a CFSE based CTL killing assay, that provides 
numerous advantages over the commonly used 51Cr release assay.     
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CHAPTER I –INTRODUCTION: ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS 
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INTRODUCTION: ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS 
Background: The spondyloarthropathies 
The spondyloarthropathies (SpA) are a subset of rheumatic diseases that consists of five 
clinically distinct diseases with overlapping phenotypes as presented by patients. These five diseases 
consist of ankylosying spondylitis (AS), psoriatic arthritis (PsA), inflammatory bowel disease 
associated arthritis, reactive arthritis, and undifferentiated spondyloarthritis.1,2 It was Moll and 
colleagues, in 1974, who defined the criteria for a subset of seronegative spondarthritides. In this 
seminal, clinical paper they outlined six criteria to define the disease, as shown in Table 1.1.3 
Highlighted in the nomenclature were the use of the prefix “spond-“ and seronegative. “Spond-“ 
referring to the vertebral involvement, and the association these diseases have with the hallmark 
phenotype of AS. The seronegative title identifies these patients as testing negative for rheumatoid 
factor (RF). RF is a serological, autoantibody biomarker that targets IgG. It is present in 85% of 
patients with rheumatoid arthritis (RA) and about 5% of healthy controls (HC).  
Spondyloarthropathy phenotype  
Clinical presentation of the spondyloarthopathies demonstrates a number of shared 
phenotypic features. As their classification implies, they are linked by an inflammatory, axial 
arthritis. Patients also commonly present with peripheral arthritis, enthesitis, dactylitis, and a 
number of extra-articular manifestations that includes uveitis, psoriasis, and inflammatory bowel 
disease.  Reports of cardiac, renal, and neurological issues are also noted. These core features are 
presented in Table 1.2. The spondyloarthropathies are also strongly associated with the class I major 
histocompatibility complex, HLA-B27. These associations, in Caucasians of western European 
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descent, are outlined in Table 1.3.  Overall to diagnose SpA, the European Spondyloarthropathy 
Study Group criteria are commonly used, Table 1.4. These criteria capture a wide disease spectrum.  
Ankylosing Spondylitis – Overview, genetic factors, and clinical diagnosis   
AS is considered to be the hallmark spondyloarthropathy, and is also the most prevalent.2 It 
is clinically defined by an insidious back pain in which the arthritis affects the spine and sacroiliac 
joints of the pelvis. Initially, this causes patients pain and stiffness, but as the disease progresses 
large numbers of patients experience ankylosis; the fusion of bones within the joint. Prior to the use 
of nonsteroidal anti-inflammatory drugs (NSAIDs) and biologics inhibiting TNF-α, patients would 
experience a striking deformity of the spine. Intriguingly, it is atypical for an autoimmune disease 
and is known to affect men more frequently than women at a ratio of 2:1 or even 3:1.2 Additionally, 
the disease is particularly challenging because it presents relatively early, when a patient is in their 
20’s-30’s.4,5  
AS has a remarkable genetic association. Familial aggregation studies have estimated that 
genetic risk factors contribute to 80-90% of the disease.6 Aligning with these estimates, 80-90% of 
patients with AS have the HLA-B27 gene. For 40 years HLA-B27 has been known to be a 
susceptibility gene7, yet it’s mechanistic contribution to the disease is still misunderstood. Animal 
models in HLA-B27, β2m transgenic rats develop spontaneous spondlyoarthritis-like disease.8 
Intriguingly, genetic ablation of the CD8 gene, which eliminates detectable CD8+ T cells, does not 
protect rats from spondyloarthritis only delaying the disease’s presentation.9 Adult thymectomy plus 
antibody mediated CD8 depletion also failed to protect HLA-B27 transgenic rats from arthritis and 
colitis.10 However, these rats are protected from intestinal inflammation and peripheral joint disease 
when raised in a germfree environment.11 This work suggests that commensal gut flora may 
contribute to pathogenesis. Such studies highlight the significance of HLA-B27, however it is 
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interesting to note that 10-20% of patients lack HLA-B27, but still develop disease and may 
represent a unique subset.  
Beyond identifying the class I major histocompatibility complex HLA-B27, other genes 
known to play critical roles in adaptive immunity have been identified by GWAS as susceptibility 
genes for AS. Recently, a large cohort of 10,000+ AS patients and 15,000+ controls profiled by 
ImmunoChip (Illumina, San Diego, CA, USA) identified 29 immune-related risk loci.12 15 of these loci 
had been identified in an earlier study.13 These results are summarized in Table 1.5.            
The diagnosis of AS is predominantly made from clinical observations. In 1963, the 
diagnostic criteria for AS were specified at the Rome conference.14 Later in 1966 it was updated, 
which led to the New York criteria for AS being used as the standard for diagnosis.15 In 1984, to 
improve diagnostic specificity and sensitivity, van der Linden, Valkenburg, and Cats synthesized the 
two aforementioned clinical criteria to form the “modified New York criteria”; which remains the 
standard to this day.16 The modified New York criteria are presented in Table 1.6. This diagnosis is 
centered on lower back pain, limitation of axial mobility, and a radiographic observation of 
sacroiliitis.  
 In addition to these cardinal features, AS patients also commonly present with a number of 
extra-articular features that include inflammatory eye involvement (acute anterior uveitis, iritis, and 
conjunctivitis), inflammatory bowel disease symptomology (colitis), skin involvement (psoriasis) and 
cardiac issues (aortic incompetence, aortitis, conduction disturbances, and heart block).17–22   
Psoriatic arthritis – Overview, genetic factors, and clinical diagnosis 
 PsA is another spondyloarthropathy disease subset defined phenotypically by the scaly, red 
well-demarcated skin plaques of psoriasis (PsO) in conjunction with elements of axial and peripheral 
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arthritis. Patients may also present with enthesitis, dactylitis, and nail disease. In 1973, Moll and 
Wright defined PsA as a “psoriasis associated with inflammatory arthritis, and usually a negative 
serologic test for rheumatoid factor”. Additionally, they proposed five subtypes: monoarthritis and 
oligoarthritis, polyarthritis, arthritis of distal interphalangeal joints with nail changes, arthritis 
mutilans, and spondylitis. Historically, there was a time period, when PsA was debated as a variant 
of RA, but it is now viewed as a distinct clinical entity.23 Similar to the other spondyloarthropathies, 
extra-articular manifestations include uveitis and inflammatory bowel disease (IBD).24 Comorbidities 
include obesity, dyslipidemia, type II diabetes, liver disease, and cardiovascular disease.24–27  
 The overall prevalence of PsA in the United States is estimated to be 0.25% (95% confidence 
interval [CI]: 0.18-0.31%). Typically, the presentation of psoriasis precedes arthritic features in PsA, 
and, in contrast to AS, the literature suggests that PsA demonstrates equal gender susceptibility.28 
HLA-B27 has been identified as a clinical predictor and is associated with a shorter time period 
between the onset of PsO and the onset of PsA.29 IL-13 has also been demonstrated as a risk locus.30 
Additional susceptibility loci associated with antigen presentation, skin barrier function, innate 
immunity, and adaptive immunity were summarized by Sukhov and colleagues. These findings are 
presented in Table 1.7.31  
PsA diagnosis is guided by the clinical observations outlined in the Classification Criteria for 
Psoriatic Arthritis (CASPAR). CASPAR relies on 5 key observations: evidence of psoriasis, nail 
dystrophy, dactylitis, seronegativity for RF, and radiological evidence of juxta-articular new bone 
formation. These criteria are outlined in Table 1.8. To be classified as having PsA a patient must have 
inflammatory articular disease affecting either the joint, spine, or enthesis with the presence of 3 or 
more of the 5 key CASPAR criteria. CASPAR has demonstrated high sensitivity and specificity.32–34 
Notably, nail involvement in the form of pitting, dystrophy, or oncholysis is a useful diagnostic clue 
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for clinicians. However, this diagnostic criteria is complicated by the observance that PsA is “usually” 
seronegative for RF. 10% of PsA patients, 10% of patients with uncomplicated psoriasis and 15% of 
the healthy population have RF present in their serum.35,36 By comparison upwards of 80% of RA 
patients are RF positive.37 Diagnosis is further complicated by the fact there is significant phenotypic 
heterogeneity between PsA patients.  
Insights into the role of the adaptive immune system in AS and PsA 
 With regard to this inconsistent observation around RF, clinicians are limited by the lack of 
diagnostic biomarkers in both AS and PsA. Moreover, given the significant heterogeneity observed in 
the SpA and the overlapping phenotypic traits these diseases are commonly misdiagnosed and often 
diagnosis is delayed. Further, radiographic assessment only identifies a phase of disease that is fairly 
advanced in its course. This highlights the critical need for a robust biomarker. There is a strong 
association between SpA and HLA-B27, making HLA-B27 typing useful. However, it omits a 
significant SpA population that is HLA-B27 negative; a population that is nearly 20% of those 
afflicted with AS and 50% of PsA patients. Acute phase reactants have also been employed as a 
guide to diagnosis, but only 50% of AS patients had elevated C-reactive protein concentrations in 
one study.38 Acute phase reactants were elevated in 40% of PsA patients. Additionally, an elevated 
erythrocyte sedimentation rate and leukocytosis were observed in one-third of PsA patients. 
Overall, laboratory assessments in the SpA lack specificity and reflect general inflammatory 
mediators.    
 In the autoimmune rheumatic diseases, the clinical utility of autoantibodies for biomarker 
use is well appreciated. Studies have shown that autoantibodies can be effective for early diagnosis, 
overall diagnosis, prognosis, response to treatment, and notably for identifying phenotypic subsets. 
For example, in rheumatoid arthritis (RA) autoantibodies targeting the enzyme PAD4 are associated 
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with more severe disease. In myositis (Myo), an autoimmune disorder targeting muscle, 
autoantibodies to aminoacyl tRNA synthetases are associated with the antisynthetase syndrome 
phenotype of myopathy.  In this condition patients present with interstitial lung disease, nonerosive 
arthritis, and mechanic’s hands. Autoantibodies targeting MDA-5 associate with dermatomyositis 
reflecting skin involvement and limited muscle damage. Similarly, in scleroderma autoantibodies 
targeting CENP A, B, and C associate with the limited phenotype restricted to patients extremities; 
and autoantibodies targeting topoisomerase I associate with the diffuse phenotype where skin 
thickening is observed broadly over the body. These findings were recently summarized in a review 
by Casciola-Rosen and Rosen, and are presented in Table 1.9.39    
It remains contested whether SpA is driven by a targeted immune response from the 
adaptive immune system or whether it is an autoinflammatory condition driven by innate immune 
components. Due to this lack of clarity, it is also possible that another unknown mechanism exists. 
However, a number of insights do hint at a role for the adaptive immune system in AS and PsA 
pathology. This hypothesis is centered on the basis of 3 key findings:  
1. immune cell infiltrates in the target tissue  
2. reports identifying autoantibodies in both AS and PsA  
3. the identification of numerous susceptibility alleles with well-defined functions in 
adaptive immunity (as discussed previously)  
These hints suggest the possibility that a useful autoantibody biomarker may be present in 
these diseases.  
 It has been demonstrated via immunohistochemical studies in both AS and PsA that 
infiltrates are present at inflamed target tissue sites. Laloux and colleagues found CD3+, CD4+, CD8+, 
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and CD20+ infiltrates at sites of enthesis in all 7 HLA-B27 positive patients they studied in AS, as well 
as 1 HLA-B27 positive PsA patient. CD3+ infiltrates were elevated in SpA samples compared to 
enthesis infiltrates in RA, and CD8+ T cells were observed to be the dominant population.40 
Organized lymphoid aggregates resembling germinal centers have also been found ectopically in PsA 
synovial biopsies. In this study 13 out of 27 PsA synovial biopsies (48%) were observed to have large 
aggregates with organized T/B cell segregation, positive immunostaining for the lymph node homing 
chemokines CXCL13, CCL21, and CXCL12, and positive immunostaining for peripheral lymph node 
adressin (PNAd); a marker of the high endothelial venule (HEV).41 Ectopic lymphoid follicles have 
also been observed in RA42–45, where numerous autoantibodies have been identified.37  
 Further support for the role of the adaptive immune system in AS and PsA is provided by a 
number of recent reports identifying autoantibodies. In AS autoantibodies to Noggin, Sclerostin, 
CD74, PPM1A, and IL-6 have been reported. It is interesting to note that two of these autoantigens, 
CD74 and IL-6, have known immune functions. CD74 is the class II invariant chain, and IL-6 is an 
inflammatory cytokine. In PsA, autoreactivities to TWEAK, STIP1, N-Rap, progranulin, thyroid 
peroxidase, thyreoglobulin, and the 20s proteasome have been reported. Additionally, 
autoreactivity to the post-translational modifications carbamylation and citrullinated vimentin have 
also been observed. These results are summarized in Table 1.10.  
In light of these connections between the adaptive immune system with AS and PsA, we 
hypothesize that a specific, antibody mediated response has a role in disease pathology. To assess 
this hypothesis we have interrogated patient serum in AS and PsA using a high throughput protein 
microarray consisting of 17,000 human proteins to broadly scan for the presence of autoantigens. 
Ultimately, the identification of a novel autoantibody has the potential for clinical use as a 
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diagnostic biomarker, and additionally may provide basic insights into the pathogenesis of these 
diseases.  
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CHAPTER II – THE IDENTIFICATION OF AUTOANTIBODIES TARGETING IFN-α AND TBX20  
IN A COHORT OF PSORIATIC ARTHRITIS PATIENTS 
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Abstract 
Objectives - The identification of autoantibodies in the autoimmune rheumatic diseases has proven 
critical in aiding clinical diagnosis, assessing disease activity, and for defining phenotypic subsets of 
patients. Here we outline a high throughput method of autoantibody identification using a human 
proteome array composed of 17,000 proteins. Using this serum profiling technique we were able to 
confirm the presence of 3 known and previously characterized myositis autoantibodies to HARS, 
MDA-5, and SNRP70. Additionally, we identified 3 other autoreactivities; to PUF60 in 
dermatomyositis, and IFN-α1 and TBX20 in a cohort of patients with psoriatic arthritis (PsA). 
Methods – Autoantibodies were identified using a human proteome array. To assess the accuracy of 
the array technology, known myositis autoantibodies were used as positive controls. Validation of 
autoreactivities to IFN-α1 and TBX20, were identified in a cohort of PsA patient serum and assessed 
via immunoprecipitation assays combining patient serum with in vitro transcribed and translated 
(IVTT) radiolabeled recombinant protein. Serum was next screened by ELISA to better understand 
the frequency of these autoantibodies. For the ELISA, sera from patients with the following diseases 
were screened: psoriatic arthritis (PsA; n=58), ankylosying spondylitis (AS; n=20), rheumatoid 
arthritis (RA; n=30), and healthy controls (HC; n=26).  
Results – The protein array identified 2 autoantibody specificities in our PsA cohort to IFN-α1 and 
TBX20. The results of our ELISA demonstrated IFN-α1 autoantibodies were present in 8.6% of PsA 
patients compared to a frequency of 0% in healthy controls. Additionally, TBX20 was identified as a 
novel autoantigen from our protein array screens. Follow-up ELISA experiments demonstrated that 
13.8% of PsA patients had the presence of TBX20 autoantibodies, compared to 3.8% found in 
healthy controls.  
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Conclusions – Protein arrays can be useful tools to confirm, as well as identify novel autoantibody 
specificities.  
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INTRODUCTION 
Psoriatic arthritis (PsA) is an inflammatory arthritis in which patients also commonly present 
with the characteristic red skin lesions of psoriasis.46 It is most commonly defined by the presence of 
peripheral arthritis, axial arthritis, enthesitis, dactylitis, and skin and nail disease. Additionally, 
subsets of patients present with extraarticular manifestations that include ocular inflammation and 
inflammatory bowel disease 47. PsA is predominantly diagnosed clinically using the international 
classification of psoriatic arthritis (CASPAR). To date a well-defined serum autoantibody associated 
with either diagnosis, prognosis, or disease activity is lacking. Consequently, PsA belongs to the 
family of seronegative spondyloarthopathies since the majority of patients do not have rheumatoid 
factor (RF) in their serum. 36,35 
The clinical utility of autoantibodies in the rheumatic diseases is well appreciated. In 
rheumatoid arthritis (RA) the presence of autoantibodies to the post-translational modification 
citrulline have proven critical for disease diagnosis, as well as being associated with a more 
aggressive course of disease.48 In myositis, autoantibodies are useful to define clinical subgroups. 
For example, autoantibodies recognizing Mi-2, MDA5, TIF1γ, and NXP-2 preferentially associate with 
dermatomyositis. In contrast, autoantibodies to SRP and HMG-CoA reductase segregate with 
autoimmune necrotizing myopathies.49 Additionally, within myositis, anti-synthetase autoantibodies 
are known to be indicative of a clinical subset that presents with interstitial lung disease.50 
Intriguingly, in the rheumatic disease systemic lupus erythematosus (SLE) 180 autoantibodies have 
been reported.51  
PsA is hypothesized to have an autoimmune mechanism. In synovial biopsies from PsA 
patients the formation of ectopic lymphoid sites has been demonstrated. These sites show an 
organized follicle structure with T/B cell separation and are positive for high endothelial venule 
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(HEV) staining.41 T cell infiltrates have also been observed in the seronegative spondyloarthropathy 
ankylosing spondylitis,40 which shares a number of phenotypic characteristics with PsA. These 
findings would suggest the presence of organized, immune-mediated processes involving both the T 
and B cell arms of the adaptive immune response. However to date, serum analysis has revealed 
limited hints of a specific autoantibody response in PsA.  
Recent reports of autoreactivities in PsA have suggested the presence of autoantibodies to 
native proteins, post-translational modifications, and pepide fragments. In their unmodified form 
TWEAK52 and STIP153 have been reported as autoantigens in PsA. PsA patients have also been 
reported to have elevated levels of antibodies targeting cabamylated proteins54 and mutated 
citrullinated vimentin.55 Dolcino and colleagues have suggested that antibodies reactive to a PsA 
peptide crossreact with a number of proteins expressed in the skin and joint.56 Additionally, 
antinuclear antibodies have been reported to be elevated in a PsA patient population.57  
To gain a better understanding of these immune mediated processes we interrogated a 
protein microarray consisting of 17,000 human proteins with patient serum from a cohort of PsA 
patients.  
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METHODS 
Patient cohorts 
Patient serum samples for PsA was obtained from the Patient Centered Outcomes Research 
in Arthritis (PCORA, n=59). PsA diagnosis was confirmed in accordance with the CASPAR criteria. 
Patients with AS (n=20) consisted of samples provided by the National Institutes of Health. AS 
diagnosis was defined by the 1984 modified New York Criteria. Patients with rheumatoid arthritis 
(RA, n=30) were also obtained from the aforementioned PCORA study. Serum samples for patients 
recently diagnosed with Lyme disease (LD, n=20) came from the Study of Lyme Disease Immunology 
and Clinical Events (SLICE study) conducted at the Johns Hopkins Lyme Disease Clinical Research 
Center. In this study only untreated, early Lyme disease as defined by the CDC are enrolled. This LD 
cohort was only screened on the protein array. Healthy control sera (HC, n=26) also came from the 
SLICE study. 
For protein array validation, myositis sera was used. Two reference serum samples were 
used, in which the reactivity was pooled from 4 total patients. Therefore, Reference 1 and Reference 
2 each contained two autoantibody reactivities. The experimenter was blinded to these specificities 
and they were confirmed after autoantigen hit lists from the array were analyzed.   
Serum profiling using human protein microarrays 
Patient serum was profiled using a human protein array composed of >17,000 human 
proteins plus nonspecific controls. The HuProt arrays were obtained from CDI labs (Baltimore, MD). 
Each recombinant human protein contains an N-terminal GST-HisX6 tag and is spotted in duplicate 
on the array. Full length recombinant human proteins were purified from Saccharomyces cerevisae, 
as previously described.1  
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All steps in the development of the array were performed at room temperature. Arrays 
were first incubated for 1.5 hr with blocking buffer (3%BSA-TBST; 0.1% Tween-20, 1x Tris-buffered 
saline). Next, the arrays were probed with patient serum at a 1:5,000 dilution and rabbit anti-GST 
antibody diluted 1:10,000 from the manufacturer’s stock (EMD Millipore; AB3282) in blocking buffer 
for a 1.5 hr incubation. Arrays were quickly washed with TBST and then underwent an extended 
wash of 5 minutes in TBST with shaking. This was repeated three times. After, the array was probed 
with the appropriate secondary antibodies diluted in blocking buffer for 1.5 h in the dark; donkey 
anti-human IgG (H+L) Cy5 [1:1,000] (Jackson ImmunoResearch, PA; 709-175-149) and goat anti-
rabbit IgG Alexa 555 [1:1,000] (Invitrogen, CA; AB21428). Arrays were again washed as stated above, 
rinsed with double-distilled H2O and dried by centrifugation.  
Array Imaging and Analysis 
Arrays were imaged using a GenePix 4000B microarray scanner (Molecular Devices, CA) and 
analyzed via GenePix Pro software.  Signal intensity was Z-score transformed (Zn) using the following 
formula Zn = (In – m)/σ. In this equation, In equals the median foreground fluorescence intensity of 
the Cy5 channel at a single protein spot, m is equal to the median foreground fluorescence intensity 
of the Cy5 channel for all spots on the array, and σ is the standard deviation of m. Array hits in the 
disease populations were determined by subtracting out any hits in which a Z-score>5 was also 
found in healthy controls, and then sorting based off of patient frequency. The program Venny was 
used for Venn diagram analysis, kindly developed by J.C. Oliveros.  
In vitro transcription and translation and immunoprecipitation (IVTT/IP) 
Immunoprecipitation experiments were performed to validate protein array hits. IFN-α1 
(NM_024013.1) and TBX20 (NM_020417.1) cDNA sequences were cloned into the pEF-Dest51 
17 
 
expression vector. 250 ng of cDNA was added to the Promega TnT T7 coupled reticulocyte lysate 
system with 35S methionine to produce a radiolabeled, in vitro transcribed and translated (IVTT) 
protein of interest. The reaction was incubated for 1.5 hours at 30°C. After, 1-5 ul of this IVTT 
reaction was incubated with 1 ul of patient serum in 500 ul of NP40 lysis buffer (1% NP40, 20mM 
Tris, 150 mM NaCl, 1mM EDTA, pH 7.4) and immunoprecipitated with protein A agarose beads 
(Pierce, #20333). Beads were centrifuged, washed, and denatured with gel application buffer plus 2-
mercaptoethanol. The immunoprecipitation product was electrophoresed on SDS-polyacrylamide 
gels and visualized by fluorography.  
ELISA 
 A 96 well plate (Costar 9018) was coated overnight at 4°C with 50 ng/well of recombinant 
protein purchased from Origene; IFN-α1 (TP310902), TBX20 (TP328815). Washes were performed 
between this and all following steps at room temperature for 1 hour. Wells were blocked with 5% 
BSA in PBS/0.05% Tween-20 (PBST), then incubated with human serum diluted 1:500 in 1% 
BSA/PBST. Goat anti-human IgG conjugated to peroxidase was used as a secondary antibody 
(Jackson ImmunoResearch, 109-036-088). After washing, wells were incubated with SureBlue 
reagent (KPL) for a colorimetric readout at an absorbance of 450 nm. To allow for plate to plate 
normalization a positive reference serum sample was used at a dilution greater than 1:500. Samples 
were determined as autoantibody positive if they were ≥ 3 standard deviations (SD) above the mean 
of healthy controls. An ELISA data point was removed from the HC descriptive statistic results, since 
it was deemed an outlier via the Grubbs’ test (α = 0.05, cutoff).   
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RESULTS 
Human proteome array screen confirms known autoantibodies to HARs, SNRP70, and MDA-5 in 
myositis serum 
Prior to using the protein array to screen for the presence of potentially novel 
autoantibodies in PsA, we first assessed the accuracy of the technology by utilizing these arrays to 
interrogate sera from myositis patients with previously characterized and known autoantibodies. 
This was done in a blinded fashion using two reference sera as described in the Methods section.  
This approach was able to identify the correct autoantibody specificities to 3 well defined myositis 
autoantigens.  Specifically, the autoantigen histidyl-transfer RNA synthetase (HisRS, Jo-1) was 
identified as the top hit with a Z-score of 27.1 (figure 2.1A) when Reference sera 1 was analyzed. An 
autoantibody response to HisRS is observed in up to 70% of patients with a myositis-interstitial lung 
disease (ILD) overlap syndrome58–60, making it particularly useful in subsetting patients for disease 
phenotype.  Also, correctly identified were the autoantigens MDA-5 and SNRP70 (figure 2.1B and 
2.1C) which were found in Reference sera 2 and 1 respectively.  The Z-score for MDA-5 was 18.4, 
and a Z-score of 9.7 was calculated for SNRP70.  Of note, reactivities to these three proteins were 
not found in sera from patients with ankylosying spondylitis (AS), psoriatic arthritis (PsA), Lyme 
disease (LD), nor healthy controls (HC). Notably, all 3 previously characterized proteins were ranked 
in the top 11 of potential hits from our array lists.  These results validated the effectiveness of the 
array technology in autoantigen identification, and thus gave us the confidence to utilize this 
approach in the identification of novel autoantigens.  
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The identification of a novel autoantibody response to PUF60 
In collaboration with colleagues we were able to use the protein array to identify PUF60 as a 
novel autoantigen that is targeted in subsets of patients with Sjogren’s syndrome (SS) and 
dermatomyositis (DM). The top PUF60 hit had a Z-score of 21.7 (figure 2.2A). Our array analysis also 
identified 2 isoforms of PUF60 in the top 15 of array hits (figure 2.2B). Autoantibodies to PUF60 
were validated by proteomics, immunoblotting, and ELISA. This work observed PUF60 to be targeted 
in 30% of SS patients and 18% of DM patients.61 
High throughput serum profiling of psoriatic arthritis identifies autoantibodies to IFN-α and TBX20 
Having established the accuracy and specificity of the protein array technology, we next 
interrogated the arrays with sera from 19 PsA patients using 20 AS patients, 20 LD patients, and 18 
healthy controls.  The AS and LD sera were used as immune mediated disease specific controls. To 
threshold our data analysis we eliminated any hits in which a Z-score greater than 5 was also found 
in healthy controls. This analysis produced a list of 80 potential autoantigen targets that were 
specific to PsA (figure 2.3A). Within our top 20 hits (figure 2.3B), we noticed functional catagories of 
proteins (figure 2.3C) that displayed reactivities to tRNA synthetases, IFN-α isoforms, and proteins 
related to apoptosis. Intriguingly, when we compared the hit lists for each disease subset we 
observed minimal overlap between hits in AS, PsA, and LD (figure 2.4). These results suggested that 
possibly the protein arrays are able to identify disease specific signatures. The top 20 autoantigen 
hits in AS and LD can be viewed in Figure 2.5.  
From our PsA specific hit list we followed up on IFN-α and TBX20 on the basis of their high Z-
scores.  
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Validation of IFN-α as an autoantigen 
Two isoforms of IFN-α were identified as targets on our hit list with robust Z-scores, 
reinforcing the strength of our analysis. The isoforms, IFNA1 and IFNA13, have a single amino acid 
difference present in the signal sequence of the protein. Thus, the mature secreted cytokines have 
identical protein sequences. In our initial array screen two serum samples displayed high Z-scores 
(figure 2.6A). To confirm the presence of autoantibodies to IFN-α in our patients we performed 
immunoprecipitation experiments using radiolabeled (35S), in vitro transcribed and translated IFN-
α1. Our IVTT/IP results confirmed the presence of autoantibodies against IFN-α in the 2 PsA patients 
initially identified (figure 2.6B). To gain a better understanding of the true frequency of this 
autoantibody in patients with PsA, we performed an ELISA to screen a larger number of patients, 
n=58. For the ELISA, positive samples were considered 3 standard deviations above the mean of 
healthy controls. Our results demonstrated that 8.6% of PsA patients (5/58) had high levels of 
autoantibodies to IFN- α, while no healthy controls were measured as positive (figure 2.6C). 
Additionally, we found particularly strong autoreactivity to IFN-α1 in one patientwith ankylosing 
spondylitis, N096 (figure 2.6D). 
Further inspection of other IFN-α isoforms on the HuProt arrays demonstrated that PsA 
patients 213 and 135 also had elevated reactivity to the IFN-α14 and and IFN-α2 isoforms (figure 
2.7). PsA patient 233 demonstrated elevated reactivity to IFN-α5 isoform (figure 2.7).   
Validation of autoantibodies targeting TBX20 
The T-box family member protein TBX20 was also identified as having a high a-score, 16.3, in 
one patient from our array screen (figure 2.8A). This protein is known to play a role in cardiac 
development62, but has never been previously reported as an autoantigen. To validate this hit, we 
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once again followed-up with IVTT/IP experiments. The results of this experiment confirmed the 
presence of autoantibodies targeting TBX20 (figure 2.8B).  To assess whether this autoantibody 
specificity was present in additional patients, we developed an ELISA and then screened  a total of 
58 serum samples from patients with PsA. Sera from other rheumatic diseases and healthy controls 
were also used. The ELISA results indicated that 13.8% of PsA patients have antibody reactivity to 
TBX20 (figure 2.8C).  
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DISCUSSION  
In these studies we implemented a high throughput screen employing a protein microarray 
composed of 17,000 human proteins to identify the presence of autoantibodies in patients with PsA 
as well as other immune mediated inflammatory disorders.  The arrays were successful in identifying 
well characterized myositis autoantibodies targeting HARs, SNRP70, and MDA-5. These proteins 
were all ranked within the top 11 on our list of potential hits. Additionally, this array technology led 
to the discovery of a novel autoantibody reactivity to PUF60. PUF60 autoantibodies were further 
validated by proteomics, immunoblotting, immunoprecipitation, and ELISA in this previously 
published study.61  
Within our cohort of PsA patient serum we identified autoantibodies targeting the proteins 
IFN-α and Tbx20. These hits were identified via array and validated by IVTT/IP and ELISA. For IFN-α, 
the IFN-α1 and IFN-α13 isoforms, which have an identical mature protein sequence, were identified. 
Our ELISA demonstrated that 8.6% of PsA patients and 0% of healthy controls were autoantibody 
positive.  
IFN-α is a secreted cytokine responsible for coordinating the host defense systems against 
intracellular pathogens. Primarily, it accomplishes this via the upregulation of antiviral, 
antiproliferative, and antigen processing proteins. IFN-α production is largely stimulated by viruses, 
but its role in anti-tumor responses has also garnered much interest. At the protein level there are 
13 isoforms of IFN-α. Interestingly, our array screen identified strong autoreactivity to the isoforms 
IFN- α1 and IFN-α13.  These isoforms have a single amino acid difference in the signal sequence, and 
thus the mature secreted proteins have identical sequences. This highlights the robustness of our 
analysis, since these proteins are printed at different locations on the array.   
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Previous reports have identified high titer autoantibodies to IFN-α2 in patients with 
autoimmune polyendocrinopathy syndrome type 1 (APS-1)63 and myasthenia gravis and/or 
thymomas.64 Recently, a protein array also identified seroreactivity to IFN-α1 and IFN-α13 in APS-1 
patients.65 APS-1 patients are deficient in the AIRE gene and in addition to autoantibodies, present 
with impaired endocrine function and chronic Candida infections.66 It is interesting to note that IFN-
α autoantibodies are known to be present in APS-1 patients with a deficiency in self-tolerance and 
are also elevated in the three autoimmune diseases we screened by ELISA. Further, it is interesting 
to note that we identified autoantibodies targeting an inflammatory cytokine; as it has been 
previously proposed that beneficial autoimmunity may work to dampen down this immune 
response. In this report investigators uncovered anti-TNF-α autoantibodies in a model of RA.67 We 
must note that upon becoming unblinded to the patient’s clinical work up, one IFN-α positive 
patient, 213, was identified as having myasthenia gravis and a benign thymoma. This may confound 
our result, as others have already identified IFN-α2 reactivity in patients with thymoma and/or 
myasthenia gravis.64 We also note that one AS patient, N096, had a strong reactivity to IFN-α1; 
demonstrated by IVTT/IP.  
We also identified autoantibodies targeting Tbx20, but more specifically the Tbx20b isoform. 
Our ELISA results demonstrated that Tbx20b autoreactivity was found in 13.8% of PsA patients. This 
is the first time Tbx20 has been reported as an autoantigen. There are 4 isoforms, of which Tbx20a 
and Tbx20b are the best studied. Tbx20b, isoform 2, is truncated at the C terminus in comparison to 
Tbx20a. Primarily, Tbx20 is known for its role in cardiac tissue development. In murine systems, it is 
reported to physically interact with NKX2-5, GATA4, and GATA5 to regulate gene programs involved 
in cardiac proliferation, chamber specification, and valvulogenesis.68 Intriguingly, missense and 
nonsense mutations have been identified in human patients with congenital heart defects (CHD) and 
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adult cardiomyopathies.62,69–71 In work by DeBenedittis and Jiao, it was observed that Tbx20a 
expression is restricted to the heart and Tbx20b expression has broader expression in the heart, 
body, and head of E12.5 mice lysates.62 Largely, Tbx20 has been studied in human and murine 
systems, however it also plays an interesting role in the excretory pathway of zebrafish with an 
essential function in cloaca development. In this study, Tbx20 was found to be downstream of Bone 
Morphogenetic Protein (BMP) signaling.72 In humans, BMP signaling plays a key role in bone and 
cartilage development73, which is interesting to account for in our study of a rheumatic disease with 
observed bone erosions.   
In future studies, it would be interesting to explore the possibility of a link between 
autoantibodies targeting Tbx20, a known regulator of cardiac tissue, and the cardiac abnormalities 
observed in subsets of PsA patients. Further, since Tbx20b is a shorter isoform it is also possible that 
these autoantibodies may be cross reactive to the Tbx20a isoform.  
We also must note that we encountered some difficulty in validating a handful of HuProt 
Array hits in the AS, PsA, and LD serum samples that were screened by this approach. It is possible 
that our primary validation experiments of IVTT/IP and ELISA may have hidden epitopes that were 
available for antibody binding on the protein arrays. In IVTT/IP and ELISA experiments we assume 
the target protein is in its tertiary structure. However, since the HuProt arrays are coated in 
nitrocellulose it is possible that the proteins printed on the array are denatured and thus largely 
linear epitopes are available for antibody binding. Consequently, these linear epitopes could have 
been masked, as a result of protein folding, in our IVTT/IP and ELISA validation experiments. It is also 
possible that the HuProt array screens are a more sensitive approach in comparison to IVTT/IP and 
ELISA. If true, validation would be difficult since current and accepted validation techniques are not 
as sensitive as our array screens.   
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Overall, we believe the use of human proteome arrays to screen for the presence of 
autoantigens represents a promising technique to uncover high-titer autoantibodies in the 
autoimmune rheumatic diseases. Here we have identified the immune cytokine IFN-α1 and the 
cardiac transcription factor Tbx20 as autoantigens. Further studies may help to elucidate whether 
these autoantibodies can be utilized in disease diagnosis, correlated with disease activity, or for 
subsetting of phenotypically distinct patients.  
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TABLES 
 
Table 1.1 – Criteria for members of the seronegative spondarthritis 
Criteria for members of the seronegative spondarthritis 
1. Negative tests for rheumatoid factor 
2. Absence of subcutaneous (“rheumatoid”) nodules 
3. Inflammatory peripheral arthritis 
4. Radiological sacroiliitis with or without classical ankylosying spondylitis 
5. Evidence of clinical `overlap’ between members of the group 
A. 2 or more of the following features: psoriasiform skin or nail lesions; ocular 
inflammation including conjunctivitis or anterior uveitis; buccal ulceration; ulceration 
of the small or large intestine; genital ulceration; genito-urinary infection (particularly 
urethritis and/or prostatitis; erythema nodosum; pyoderma gangrenosum; 
thrombophlebitis).   
6. Tendency of familial aggregation 
Source: Moll and Wright 1974 
 
 
 
 
Table 1.2 - General features of the spondyloarthropathies  
 Radiographic sacroiliitis with or without accompanying spondylitis 
 Variable inflammatory peripheral arthritis, enthesitis, and dactylitis 
 Association with chronic inflammatory bowel disease 
 Association with psoriasis and other mucocutaneous lesions 
 Tendency for anterior ocular inflammation 
 Increased familial incidence 
 Occasional aortitis and heart block 
 No association with rheumatoid factor (RF) 
 Strong association with HLA-B27 
Source: Khan, M.A. Ann. Intern. Med. (2002) 
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Table 1.3 – Spondyloarthropathy association with HLA-B27 in caucasians of western European 
descent 
Disease HLA-B27 prevalence  
(approximate) 
Ankylosing spondylitis 80-90% 
Reactive arthritis 40-80% 
Juvenille spondyloarthropathy  70% 
Enteropathic spondyloarthritis 35-75% 
Psoriatic spondyloarthritis 40-50% 
Undifferntiated spondyloarthropathy 70% 
Acute anterior uveitis (acute iritis) 50% 
Aortic incompetence with heart block 80% 
Source: Khan, M.A. Ann. Intern. Med. (2002) 
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Table 1.4 – The European Spondyloarthropathy Study Group Criteria 
Criteria Definition 
A. Inflammatory spinal pain; 
              with ≥ 4 of the following 5 components 
History of or current symptoms of spinal pain 
(low, middle, and upper back or neck region) 
1. At least 3 months in duration  
2. Onset before 45 years of age  
3. Insidious (gradual) onset  
4. Improved by exercise  
5. Associated with morning spinal stiffness  
B. Synovitis Past or present asymmetric arhritis, or arthritis 
in the lower limbs 
C. Spondyloarthropathy Presence of inflammatory spinal pain OR 
synovitis AND one or more of the following 
conditions: 
- Family history: first or second degree 
relatives with ankylosing spondylitis, 
psoriasis, acute iritis, reactive arthritis, 
or inflammatory bowel disease 
- Past or present psoriasis 
- Past or present ulcerative colitis or 
Crohn’s disease 
- Past or present pain alternating 
between the two buttocks 
- Past or present enthesitis 
- Episode of diarrhea occuring 1 month 
before the onset of arthritis 
- Nongonococcal urethritis or cervicitis 
occuring 1 month before the onset of 
arthritis 
- Bilateral grade 2-4 sacroiliitis or 
unilateral grade 3-4 sacroiliitis  
Source: Khan, M.A. Ann. Intern. Med. (2002) 
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Table 1.5 – Ankylosing spondylitis susceptibility genes/loci identified by genome-wide association 
studies 
Summary of  ankylosing spondylitis susceptibility genes/loci identified by genome-wide association 
studies  
Loci previously associated with AS  
RUNX3 Runt-related transcription factor 3 
IL23R Interleukin 23 receptor 
GPR25  G-protein-coupled receptor 25 
KIF21B Kinesin family member 21B 
Intergenic Chromosome 2p15 
PTGER4 Prostaglandin E receptor 4  (subtype EP4) 
ERAP1 Endoplasmic reticulum aminopeptidase 1 
IL12B Interleukin 12B 
CARD9 Caspase recruitment-domain family member 9 
LTBR Lymphotoxin β-receptor (TNFR superfamily, member 3 
TNFRSF1A Tumor-necrosis factor-receptor superfamily member 1A 
NPEPPS Aminopeptidase puromycin-sensitive 
TBKBP1 TNFR-associated factor family member-associated nuclear factor-κβ-binding kinase I-
binding protein 
TBX21 T-box 21 
Intergenic Chromosome 21q22 
New loci associated with AS 
IL6R Interleukin 6 receptor 
FCGR2A Fc fragment of immunoglobulin G, low-affinity IIa, receptor (CD32) 
UBE2E3 Ubiquitin-conjugating enzyme E2E 3 
GPR35 G-protein-coupled receptor 35 
BACH2 BTB and CNC homology 1, basic leucine-zipper transcription-factor 2 
ZMIZ1 Zinc finger, MIZ type-containing 1 
NKX2-3 NK2 homeobox 3 
SH2B3 Src homology 2B adaptor protein 3 
GPR65 G-protein-coupled receptor 65 
IL27 Interleukin 27 
SULT1A1 Sulfotransferase family cytosolic 1A 
NOS2 Nitric oxide synthase 2 
TYK2 Tyrosine kinase 2 
ICOSLG Inducible T-cell costimulator ligand 
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Table 1.6 – The modified New York Criteria for ankylosing spondylitis diagnosis 
Modified New York Criteria for Ankylosing Spondylitis (1984) 
Diagnosis 
Clinical criteria 
1. Low back pain for at least 3 months, improved by exercise 
and not relieved by rest. 
2. Limitation of lumbar spine motion in saggittal and frontal 
planes. 
3. Chest expansion decreased relative to normal values for 
age and sex 
 
Radiographic criteria 
4a.  Unilateral sacroiliitis grade 3-4 
4b.  Bilateral sacroiliitis grade 2-4 
Grading 
1. Definite AS if (4a or 4b) AND any clinical criterion (1-3) 
2. Probable AS if: 
a. 3 clinical criteria are present 
b. The radiographic criterion is present without any 
signs or symptoms satisfying the clinical criteria. 
(Other causes of sacroiliitis should be considered) 
Source: Van der Linden et al., Arthritis Rheum 1984; 27: 361-368 
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Table 1.7 – Psoriatic arthritis susceptibility genes/loci  
Antigen presentation  
HLA-Cw*0602 Strong association with PsV, earlier disease onset and positive family history 
HLA-B27 Risk allele for axial joint disease in PsA 
HLA-B39 Associated with PsA; similar to HLA-B27 encodes electronegative B pockets 
HLA-B40 Protective against PsA; encodes electropositive B pockets 
ERAP1 Variants have decreased aminopeptidase activity involved in antigen processing   
PSMA6 Encodes a subunit involved in MHC class I antigen processing 
Skin barrier function 
LCE3 LCE3C_LCEB-del is thought to increase susceptibility to exogenous substances due to 
impaired barrier function in PsV 
Innate immunity 
CARD14 Activates NF-κβ which upregulates IL-8 AND CCL20 in skin, and controls early osteoclast 
differentiation in bone 
NOS2 Encodes inducible nitric oxide synthase, which has increased expression in psoriatic 
plaques and synovium 
TNIP1, TNFASIP3 These genes control the ubiquitination and degradation of Iκβ-a, which inhibits NF-κβ 
signaling by retaining it in the cytoplasm 
NFKBIA Encodes Iκβ-a 
Adaptive immunity 
IL12B Increased IL12B gene expression has been found in psoriatic plaques  
IL23R, IL23A Th17 associated phenotype 
IL12RB2, TYK2 IL-12 receptor plays a key role in the Th1 phenotype. TYK2 is required for IL-12B1 
signaling 
TRAF3IP2 Encodes the adaptor protein CIKS (Act1), which has a role in IL-17 mediated inflammation 
Source: Sukhov, A. Clin. Rev. Allergy Immunol. (2016) 
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Table 1.8 – The CASPAR classification criteria for PsA 
Grading: To be classified as having PsA, a patient must have inflammatory articular disease (joint, 
spine, enthesis) with ≥ 3 of the following 5 points: 
Criterion Description 
1. Evidence of psoriasis (one of a, b, or c)  
a. Current psoriasisa Psoriatic skin or scalp disease currently 
present, as judged by a rheumatologist or 
dermatologist 
 
b. Personal history of psoriasis A history of psoriasis obtained from a patient 
or family physician, dermatologist, 
rheumatologist, or other qualified healthcare 
professional 
 
c. Family history of psoriasis A history of psoriasis in a first- or second-
degree relative by patient report 
 
2. Psoriatic nail dystrophy Typical psoriatic nail dystrophy, including 
onchyolysis, pitting, and hyperkeratosis 
observed on current physical examination 
 
3. Negative test for RF By any method except latex, but preferably 
ELISA or nephelometry, according to the local 
laboratory reference range 
4. Dactylitis  
a. Current Swelling of an entire digit 
b. History A history of dactylitis recorded by a 
rheumatologist 
 
5. Radiological evidence of juxta-articular 
new bone formation 
Ill-defined ossification near joint margins 
(excluding osteophyte formation) on plain x-ray 
films of hand or foot 
CASPAR, ClASiffication criteria for Psoriatic Arthritis; RF. rheumatoid factor; ELISA, enzyme-linked 
immunosorbent assay 
a Current psoriasis scores 2; all other items score 1 
Source: Primer on Rhuematic Diseases 
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Table 1.9 – Examples of phenotype and autoantibody association 
Autoantigen Phenotypic features 
  
Autoimmune myopathies 
Aminoacyl tRNA synthetases Antisynthetase syndrome: myopathy, interstitial lung 
disease, nonerosive arthritis, fever, and mechanic’s hands 
MDA5 Dermatomyositis with mild or absent muscle disease 
Scleroderma 
Topoisomerase I Diffuse cutaneous scleroderma 
CENP A,B, and C Limited cutaneous scleroderma 
Rheumatoid Arthritis 
PAD4 More severe disease 
Source: Rosen, A. Annu. Rev. Immunol (2016) 
 
 
 
Table 1.10 – Reported autoantigens in AS and PsA 
Autoantigens in AS 
Autoantigen Author 
Noggin Tsui, F. Ann. Rheum Dis. (2014) 
Sclerostin Tsui, F. Ann. Rheum Dis. (2014) 
CD74 Baerlecken, NT. Ann. Rheum Dis. (2014) 
PPM1A Kim, YG. Arthritis Rheumatol. (2014) 
IL-6 Wright, C. Mol. Cell Proteomics (2012) 
Autoantigens in PsA 
Tweak1 Guis, S. J. Transl. Med. (2016) 
STIP1 Maejima, H. PLOS ONE (2014)  
N-Rap Dolcino, M. PLOS ONE (2014) 
Progranulin Thurner, L. Arthritis Res. Ther. (2013) 
Thyroid peroxidase Peluso, R. J Rheumatol (2011) 
Thyreoglobulin Peluso, R. J Rheumatol (2011) 
20s proteasome Colmenga, I. . J Rheumatol (2008) 
Carbamylation Chimenti, M.S. Autoimmun. Rev. (2015) 
Citrullinated vimentin Dalmady, S. Clin. Dev. Immunol. (2013) 
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Figure 2.4 The HuProt array identifies unique autoantigen signatures present in AS, PsA, and 
LD. Hit lists specific to each disease subset were analyzed via Venn diagram demonstrating minimal 
overlap between the autoantigens recognized in each disease.   
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CHAPTER III – INTRODUCTION: NONCLASSICAL MHC Ib IN T CELL DEVELOPMENT 
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INTRODUCTION 
CD8+ effector function 
CD8+ T cells play a critical role in the body’s response to intracellular bacteria, viruses, and 
tumors. By recognizing foreign or mutated peptides presented by the major histocompatibility 
complex (MHC) class I, they are capable of eliminating infected, oncogenic, and even stressed cells. 
This process is known as cell-mediated immunity, and is critical for limiting and stopping the damage 
caused by disease.  
In the periphery, this effector function, is composed of five key steps. First, the T cell 
receptor (TCR) of the CD8+ T cell recognizes peptide in the context of MHC class I on a target cell. 
Upon antigen recognition, TCRs will aggregate and dimerize at the central supramolecular activation 
complex (c-SMAC). This TCR clustering results in an intracellular signaling cascade initiated from the 
CD3 co-receptor complex and leading to the phosphorylation of intracellular activation motifs 
(ITAMs). The downstream components of this signaling result in the polarized release of granules 
containing three CD8 effector molecules; perforin, granzyme, and granulysin. These molecules are 
released at the immunological synapse and exquisitely directed at the target cell. This directed 
release allows the serine protease granzyme to enter the cytosol of the target cell via complexes of 
perforin and sergylcin. Here, granzyme activates a caspase cascade that culminates in target cell 
apoptosis; thus ridding the body of an infected or transformed cell. 
In summary the five key steps described are: 1) Epitope recognition by the TCR 2) Immune 
synapse formation 3) Intracellular signaling 4) Granule release 5) Target cell apoptosis. 
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CD8+ T cell development 
However, before a CD8+ T cell can play this vital role of immune surveillance, it must first 
undergo an intricate and rigorous developmental process. The core of this developmental process 
resides in the thymus. Within this setting, a developing T cell must refine the ability to recognize 
self-MHC while also balancing the task of avoiding auto-reactivity. This stage of development has 
been termed “T cell selection”, and the dilemma faced parallels that of the fairy tale protagonist 
Goldilocks. Ultimately, the T cell must develop its antigen receptor to be “just right”. To develop an 
appropriate TCR repertoire thymocytes, the T cell precursors, undergo positive and negative 
selection as they migrate through the cortex and medulla regions of the thymus. 
With regard to T cells that eventually become CD8+ their TCR must recognize MHC class I 
during development. The ability of an immature thymocyte to recognize self-peptide:MHC class I 
complexes with intermediate affinity allows it to be positively selected.  This recognition leads to a 
signal that up-regulates TCR expression and ceases expression of the CD4 co-receptor. At this time, 
CD8 expression is maintained on the cell surface. Now, as a single positive thymocyte, the CD8+ T 
cell continues to migrate through the thymus needing to avoid negative selection if it is to survive 
and mature into the periphery. It is understood that during negative selection auto-reactive cells are 
eliminated. Negative selection is initiated by strong recognition of self-peptide:MHC and leads to 
thymocyte apoptosis.  
Studies on T cell development and TCR restriction have primarily focused on the role of the 
highly polymorphic, classical MHC class Ia molecules (MHC Ia). However, only recently has the focus 
shifted to the role being played by non-classical MHC class Ib (MHC Ib) molecules during T cell 
development. At the genetic level, non-classical MHC Ib molecules are defined by their incredibly 
low polymorphism. This level of evolutionary conservation stands in stark contrast to the hundreds 
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of alleles identified for class Ia molecules. Further, it has been demonstrated that classical MHC Ia 
selection occurs on thymic epithelial cells (TECs), while non-classical MHC Ib selection can be 
orchestrated by both TECs and hematopoietic cells (HCs).74,75 Intriguingly, studies have shown that 
MHC Ib-restricted (nonclassical) CD8+ T cells have a distinct “innate-like” phenotype, in comparison 
to MHC Ia-restricted (classical) CD8+ T cells. This innate-like phenotype is defined by high levels of 
CD44 expression on naïve, murine T cells76, and the ability to rapidly produce cytokines upon in vitro 
stimulation. Additionally, MHC Ib restricted T cells have been observed to mount a quicker immune 
response to Listeria monocytogenes (LM).76,77  
Qa-1 overview 
Qa-1 is an MHC Ib molecule with only four known alleles.78 Predominantly, it displays a 
single peptide within its’ hydrophobic binding pocket. This peptide is derived from the proteasome 
processed signal sequence of the MHC Ia molecules H-2D and H-2L; and requires TAP (transporter 
associated with antigen processing) dependent transport into the endoplasmic reticulum (ER). This 
peptide has been named the Qa-1 determinant modifier or Qdm. Qdm is composed of the 
nonameric amino acid sequence AMAPRTLLL. Peptide elution studies have demonstrated that Qdm 
comprises 70% of the total peptide content of Qa-1.79  
Moreover, it is important to note that Qa-1 is the otholog to the human HLA-E molecule. 
Despite only 73% amino acid sequence homology, HLA-E largely presents a similar Qdm peptide with 
the sequence VMAPRTLLL. HLA-E is also non-polymorphic having only two known alleles in the 
human population.78 Functionally, these orthologs have similar roles in the murine and human 
immune system, highlighting the translational appeal of studying Qa-1.  
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Qa-1 in missing self recognition 
Qa-1 is most well studied for its’ role as a natural killer (NK) cell receptor. The Qa-1:Qdm 
complex serves as a ligand for particular NKG2 family receptors that form heterodimers with CD94. 
A higher binding affinity has been demonstrated for the inhibitory CD94/NKG2A receptor, in 
comparison to the activating CD94/NKG2C/E receptors.80 Consequently, this role positions Qa-1 at a 
critical node of antigen processing surveillance. Under normal conditions appropriate levels of Qa-
1:Qdm on the cell surface transmits an inhibitory signal to probing NK cells and protects the cell 
from lysis. However, during times of MHC Ia downregulation, which may result from viral infection 
or tumorigenesis, lowered availability of Qdm reduces surface levels of Qa-1:Qdm, thus making 
these cells more susceptible to NK cell mediated lysis in a process that has been termed “missing 
self” recognition.81 This interaction also crosses over into adaptive immunity, where it has been 
observed that approximately 5% of circulating CD8+ T cells are double positive for CD94 and NKG2A 
expression.82     
Diverse peptide presentation by Qa-1 
Despite the dominance of Qdm presentation by Qa-1, multiple groups have reported its’ 
ability to present a diverse array of foreign and self-peptides. During intracellular bacterial infection 
Qa-1 can present epitopes from Salmonella typhimurium,83 and Qa-1 restricted αβ CTLs have been 
identified in mice after infection with LM.84–88 A greater number of pathogen derived peptides have 
been found to bind HLA-E that include: Salmonella, Listeria monocytogenes, LCMV, HIV, EBV, HCV, 
and Mycobacterium tuberculosis.89,90 Numerous self-peptides have also been identified that bind 
Qa-1 including HSP60 in the absence of QDM91, Fam49b in ERAAP (endoplasmic reticulum 
aminopeptidase associated with antigen processing) knockout cells92, and an additional eighty-four 
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in TAP deficient cell lines.93 These observations provide insights into Qa-1’s ability to monitor 
antigen processing defects in an adaptive immune context, as a ligand for the TCR of CD8+ T cells.  
CD8+ regulatory T cells 
Additionally, there are a number of reports suggesting that Qa-1 restricted αβ T cells may 
play an important regulatory role. The observance that injecting naïve rats with an irradiated (or 
mitomycin C treated), myelin basic protein specific, CD4+ T cell line protects these rats from the 
induction of experimental allergic encephalomyelitis (EAE) has opened the door for further inquiry.  
This therapeutic strategy has been termed T cell vaccination (TCV). Studies of TCV in humans and 
rats have identified a CD8+ T cell population that specifically recognizes the pathogenic, vaccine T 
cells.94,95 Work from the laboratory of Leonard Chess’s lab has identified Vβ8-specific Qa-1-restricted 
CD8+ T cells that are induced by TCV and capable of lysing a CD4+ T cell clone that expresses Vβ8.96 
Recently, new observations have suggested that Qa-1 restricted CD8+ regulatory cells (CD8+ Tregs) 
monitor follicular T helper cells (Tfh). Using a genetic model to disrupt TCR/CD8 recognition of Qa-1, 
work by Kim and colleagues uncovered the development of a systemic-lupus-erythematosus-like 
autoimmune disease driven by autoantibodies.97 Moreover, in a mouse model of collagen-induced 
arthritis these CD8+ Tregs were observed to eliminate autoreactive Tfh and Th17 cells, thereby 
inhibiting disease development.98       
The observations that Qa-1 can alert CD8+ T cells of the adaptive immune system to antigen 
processing defects, in combination with research bridging an innate phenotype associated with 
positive selection by MHC Ib on HCs hints at an intriguing role for Qa-1. Is it possible that these cells 
have evolved to rapidly eliminate dangerous cells with compromised antigen processing systems? 
Such a role may prove significant since viral infection, stress, and tumorigenesis have all been 
demonstrated to impede appropriate antigen processing. In these circumstances the role of Qa-1 
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and HLA-E is understudied. Further, little clarity has been provided on the role CD8+ Qa-1-restricted 
T cells have in a regulatory context. Here we outline the development of a transgenic mouse model 
to investigate these hypotheses. This system will allow us to study the role played by Qa-1 in 
nonclassical T cell development and determine if positive selection can impart an innate phenotype 
on CD8+ T cells. Additionally, we aim to assess whether the existence of an innate, positively 
selected Qa-1 CD8+ T cell population has evolved to provide immunosurveillance against antigen 
processing defects. Further, it is possible that this reductionist system will lead to an enrichment of 
the CD8+ Treg population, and thus make this rare cell lineage easier to study. During the 
development of this mouse model, we have also optimized a flow-cytometry based CTL killing assay 
to serve as a replacement for the dated and cumbersome 51Cr release assay. This method is also 
described.      
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CHAPTER IV – THE DEVELOPMENT OF A scQa-1b MOUSE MODEL TO ASSESS  
T CELL DEVELOPMENT AND PHENOTYPE 
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ABSTRACT 
Objectives – We have designed 3 DNA constructs that covalently link the Qa-1b sequence to β2-
microglobulin (β2m) with the overall goal of selecting the construct that best mimics native Qa-1b 
function for use in a transgenic mouse model. We refer to these constructs as single-chain Qa-1b 
(scQa-1b). Upon breeding this scQa-1b transgenic with mice deficient in β2m -/-, we will have 
designed a system where Qa-1b is the sole MHC I molecule present for T cell selection. This strategy 
will provide a unique, reductionist environment to study nonclassical, Qa-1 dependent T cell 
development and further interrogate CD8+ T cells present in the periphery. Peripheral CD8+ T cells 
will be thoroughly investigated with regard to localization, phenotype, TCR repertoire, cytokine 
secretion, and proliferation abilities.    
Methods – 3 DNA constructs were cloned for potential transgenic use. These transgenes (Tg) 
contained either the genomic DNA (gDNA) or complementary DNA (cDNA) sequence of Qa-1b 
followed by a repeating linker sequence to connect it to the sequence encoding β2m. To assess the 
functionality of these engineered constructs, murine L cells, which are Qa-1 deficient, were 
transfected with each. Expression levels were measured via western blot and flow cytometry. 
Functionality was assessed in a CFSE (carboxyfluorescein succinimidyl ester) based CTL killing assay.  
Results – Results from SDS-PAGE experiments determined that two transgenes were expressed and 
appropriately N-glycosylated. These two transgenes were Tg 2 and Tg 26. Further, flow cytometry 
experiments demonstrated that these two transgenes were expressed on the cell surface. CFSE 
killing assays demonstrated that both Tg 2 and Tg 26 permitted target cell lysis in a peptide 
concentration dependent and effector cell dependent manner. We selected Tg 2, on the basis of 
superior expression and CTL recognition, for transgenic development. Unfortunately, in a developing 
in vivo murine system a CD8+ T cell phenotype was not observed.         
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Conclusions – The development of a scQa-1b transgenic mouse model in theory provides a unique 
tool to study nonclassical, Qa-1 dependent T cell selection and the phenotypes of uncommon CD8+, 
Qa-1 restricted peripheral T cells. In vitro assays validated robust transgene expression and 
functional CTL recognition. However, the ability to detect peripheral CD8+ T cells in vivo failed. 
These results suggest that different genetic or protein regulatory mechanisms could be present 
during murine development that were not accounted for.   
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INTRODUCTION 
MHC class I molecules serve as sensors of a cell’s internal environment. During times of 
intracellular infection, tumorigenesis, and stress MHC I molecules are capable of alerting 
lymphocytes to dispose of damaged cells. Structurally, MHC I molecules are comprised of three n-
terminal domains referred to as α1, α2, and α3 followed by a transmembrane domain and a c-
terminal domain that extends into the cytoplasm of the cell. This structure is referred to as the 
heavy chain and associates noncovalently with beta-2 microglobulin (β2m), also referred to as the 
light chain. A key component of MHC class I’s ability to identify damaged cells resides in between 
the α1 and α2 domains where short peptide segments ranging from eight to ten amino acids can 
bind the groove.89 The presence of this peptide, MHC I, and β2m form a trimer on the cell surface 
that serves as a ligand for the T Cell Receptor (TCR) and certain natural killer (NK) cell receptors.   
Within the MHC class I family there exists a division between Ia and Ib molecules. Classical 
MHC Ia (MHC Ia) molecules, which include H-2K, D, and L, are defined by extensive allelic variability. 
On the other hand nonclassical MHC Ib (MHC Ib) molecules are characterized by incredibly low 
polymorphism.  Qa-1 belongs to the MHC Ib subgroup having only four known alleles.78 Another 
intriguing feature of Qa-1 is that it largely displays a single peptide within its’ hydrophobic binding 
pocket. This peptide is derived from the proteasome processed signal sequence of the MHC Ia 
molecules H-2D and H-2L and requires TAP (transporter associated with antigen processing) 
dependent transport into the endoplasmic reticulum (ER). This peptide has been named the Qa-1 
determinant modifier, Qdm, and is composed of the nonameric amino acid sequence AMAPRTLLL. It 
has been calculated from peptide elution studies that Qdm makes up 70% of the total peptide 
content of Qa-1.79 It is also worth noting that Qa-1 is the ortholog to the human HLA-E molecule. 
Despite only 73% amino acid sequence homology, HLA-E typically presents a similar Qdm peptide 
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with the sequence VMAPRTLLL. HLA-E is also non-polymorphic having only two known alleles in the 
human population.78 Functionally these orthologs play similar roles in the murine and human 
immune system, highlighting the translational appeal of studying Qa-1. 
During T cell development positive and negative selection are mediated by interactions 
between the T cell TCR and MHC class I. Primarily, studies on T cell development and TCR restriction 
have focused on the role of the highly polymorphic, classical MHC Ia molecules. However, only 
recently has the focus shifted to the role being played by nonclassical MHC Ib molecules during T cell 
development. It has been demonstrated that classical MHC Ia selection occurs on thymic epithelial 
cells (TECs), while non-classical MHC Ib selection can be orchestrated by both TECs and 
hematopoietic cells (HCs).74,75 Intriguingly, studies have shown that MHC Ib-restricted (nonclassical) 
CD8+ T cells have a distinct “innate-like” phenotype, in comparison to MHC Ia-restricted (classical) 
CD8+ T cells. This innate-like phenotype is defined by high levels of CD44 expression on naïve, 
murine T cells76, and the ability to rapidly produce cytokines upon in vitro stimulation. Further, MHC 
Ib restricted, CD8+ T cells have been observed to mount a quicker immune response to Listeria 
monocytogenes (LM).76,77 
Additionally, there are a number of reports suggesting that Qa-1 restricted αβ T cells may 
play an important regulatory role. The observance that injecting naïve rats with an irradiated (or 
mitomycin C treated), myelin basic protein specific, CD4+ T cell line protects these rats from the 
induction of experimental allergic encephalomyelitis (EAE) has opened the door for further inquiry.  
This therapeutic strategy has been termed T cell vaccination (TCV). Studies of TCV in humans and 
rats have identified a CD8+ T cell population that specifically recognizes the pathogenic, vaccine T 
cells.94,95 Work from the laboratory of Leonard Chess’s lab has identified Vβ8-specific Qa-1-restricted 
CD8+ T cells that are induced by TCV and capable of lysing a CD4+ T cell clone that expresses Vβ8.96 
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Recently, new observations have suggested that Qa-1 restricted CD8+ regulatory cells (CD8+ Tregs) 
monitor follicular T helper cells (Tfh). Using a genetic model to disrupt TCR/CD8 recognition of Qa-1, 
work by Kim and colleagues uncovered the development of a systemic-lupus-erythematosus-like 
autoimmune disease driven by autoantibodies.97 Moreover, in a mouse model of collagen-induced 
arthritis these CD8+ Tregs were observed to eliminate autoreactive Tfh and Th17 cells, thereby 
inhibiting disease development.98       
Here we have outlined a strategy for a unique mouse model to elucidate the role of Qa-1 
dependent, nonclassical T cell selection during development. This scQa-1b; β2m -/- model also 
enables us to interrogate the phenotypes of Qa-1 restricted, peripheral CD8+ T cells. Such work will 
elucidate the prospects of the presence of an innate-like CD8+ T cell population and also CD8+ 
Tregs.   
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METHODS 
scQa-1bcloning 
Three single-chain Qa-1b DNA constructs were cloned, to assess CD8+ T cell development. 
The single-chain nomenclature refers to the insertion of a short peptide linker that covalently links 
the heavy chain Qa-1b to β2-microglobulin (β2m) for appropriate expression on the cell surface and 
antigen presentation. The prefix Tg is used to identify these constructs since they are potential 
transgenes. Tg 2 was driven by the H-2Dd promoter, followed by β2mb cDNA, a 20 amino acid linker 
composed of a cluster of four glycine molecules followed serine repeated four times (G4S)4, next to 
the genomic sequence of Qa-1b. Tg 26 was driven by the H-2Kb promoter, followed by an intronic 
sequence, β2mb cDNA, a 15 amino acid linker composed of four glycine molecules followed serine 
repeated three times (G4S)3, next to the cDNA sequence of Qa-1b. Tg30 was driven by the H2-Dd 
promoter, followed by β2mb cDNA, a 15 amino acid linker composed of four glycine molecules 
followed serine repeated three times (G4S)3, next to the genomic sequence of Qa-1b. These 
constructs are illustrated in Figure 4.2. 
Transfection of scQa-1bin L cells 
The murine, adherent fibroblast L cell line (tk-) (Ltk-) was used for target cells since they do 
not express endogenous Qa-1. Cells were transfected with the scQa-1b constructs via 
electroporation. In summary, 10x106 cells were electroporated at a voltage of 950 , capacitance of 
25 μFD, and overall field strength of 2,375, in calcium and magnesium free Hank’s Buffered Saline 
Solution with 20 ug of each DNA construct. A Bio-Rad gene pulser was used for the electroporation. 
Serial diluton in a 96 well plate allowed for the outgrowth of single clones. After transfection cells 
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were maintained in media consisting of DMEM, 10% FBS, P/S/Q, and G418 to allow for drug 
resistant selection.  
 Detection of scQa-1b expression 
Expression levels were determined using two techniques: western blotting and flow 
cytometry. For western blotting scQa-1b transfected L cell clones (Tg 2, Tg 26, and Tg 30) were lysed 
and denatured in sample buffer with 2-merccaptoethanol followed by 3 minutes of boiling. Lysates 
were run on 10% SDS-PAGE gels and transferred to nitrocellulose. The 6A8.6F10.1A6 antibody at a 
concentration of 1:500 was used for primary detection. Anti-mouse IgG horseradish peroxidase 
conjugated antibody at a concentration of 1:10,000 was used for secondary detection and visualized 
using chemiluminescence (ThermoFisher, Pierce SuperSignal West Pico).   
CFSE based killing assay 
Target cells and bystander cells were labeled at two different concentrations of CFSE. 
CFSELow targets were labeled at a final concentration of 0.42 uM and CFSEhigh bystander cells were 
labeled at a concentration of 5 uM. In brief, a description of the labeling process. A stock solution of 
CFSE (Biolegend, 422701) was diluted in PBS and incubated with the relevant cell line for 10 minutes 
at 37°C, while protected from light (total volume was equal to 1 ml). Staining was quenched by 
adding 10 ml of ice cold DMEM with 10% FBS. Cells were washed by pelleting via centrifugation, 
washed 1x with PBS, and then resuspended in RPMI 1640 with 10% FBS plus P/S/Q supplements. 
Cells were plated at the appropriate cell count in a 96 well round bottom dish. Then these target 
and bystander cells were incubated with the appropriate CTL clone, D5D2 or 524.D11, and the plates 
were briefly centrifuged to promoted cell-to-cell contact. The CTL mediated killing incubation took 
place for 4 hours at 37°C in a tissue culture incubator. After this incubation cells were harvested for 
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analysis via flow cytometry. The plates were centrifuged to pellet targets, bystanders, and CTL 
clones. Media was next aspirated off. Since L cells are adherent, the cells were incubated with 
Cellstripper for 15 minutes. Cells were next stained with TO-PRO-3 iodide (ThermoFisher, T3605) at 
a concentration of 1 ul per 100,000 cells. Further, anti-CD8 conjugated PE antibody was included to 
gate out the CD8+ CTL clones. This staining cocktail was incubated with cells for 25 minutes. After, 
cells were washed 1x and analyzed on a FACS Calibur.   
Transgenic development 
Transgenic mouse model development was conducted by the gene core at the University of 
Utah in collaboration with Dr. Peter Jensen’s laboratory. Tg 2 was linearized and injected into the 
pronucleus of a C57BL/6 zygote, prior to breeding to β2m -/- mice.  
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RESULTS 
The design of a single-chain Qa-1b molecule 
To understand the role that Qa-1 serves during T cell development, we have designed a 
transgenic mouse model that expresses Qa-1 as the sole MHC I molecule. An illustration of this 
model is presented in Figure 4.1. To start, three DNA constructs that covalently link β2mb to the 
genomic (gDNA) or complementary (cDNA) sequence of Qa-1b via an amino acid linker were 
designed. We refer to these molecules as scQa-1b. The amino acid linker is composed of repeats of 
four glycine and one serine (G4S). A detailed map of these potential transgenes (Tg) can be seen in 
Figure 4.2.  
These three constructs have slightly varied components in the promoter, linker, and Qa-1b 
gene. Tg 2 and Tg 30 are both driven by the H2-Dd promoter and contain the genomic sequence of 
Qa-1b. They also differ in the size of their amino acid (aa) linker. Tg 2 has a 20 aa linker and Tg 30 has 
a 15 aa linker. This linker or spacer is included to create physical distance and foster a β2mb:Qa-1 
interaction that mirrors the wild-type interaction. Tg 26 is the most divergent of the constructs 
utilizing the H-2Kb promoter, a 15 aa linker, and a Qa-1b cDNA sequence. Additionally, this sequence 
contains an intron aimed at enhancing expression in the transgenic system.99 
Validation of scQa-1b expression 
To determine that the scQa-1b molecules could be expressed and remain intact, we stably 
transfected the murine L (tk-) cell line (Ltk) with each transgene. This fibroblast cell line is Qa-1 
deficient making them a choice cell line for scQa-1b transfection. Clones were isolated via limiting 
dilution in a ninety-six well plate and expression was assessed by SDS-PAGE and flow cytometry 
(figure 4.3). The wild-type Qa-1 migrates at 44 kDa and is detected in wild-type murine PBMC lysate; 
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while the scQa-1b constructs migrate at a molecular weight of 60 kDa, representing the convalent 
linkage of β2mb via an amino acid linker. The higher and fainter band represents the mature N-
glycosylated form (figure 4.3A). Two clones for each transgene with strong expression were 
observed for Tg 2 and Tg 26, while Tg 30 levels were nearly undetectable by western blot.  
Surface expression of scQa-1b was tested by flow cytometry. Only one clone, 30E, failed to 
consistently express scQa-1b on the cell surface. The remaining clones had noticeable surface 
expression as determined by histogram analysis and mean fluorescence intensity. These results are 
displayed in Figure 4.3B and Figure 4.3C.  
Functional recognition of scQa-1b CTL clones 
To determine if the scQa-1b was functional as an antigen presentation molecule, we 
optimized a CFSE based killing assay. First, target cells (scQa-1b+) and bystander cells (scQa-1b(-)) 
were labeled with CFSE at two different concentrations. Target cells were CFSELow [0.42uM]final and 
bystanders CFSEHigh [5uM]final. This 10-fold difference in CFSE labeling concentrations produced two 
distinct, clearly labeled cell populations that could be easily detected and seperated by flow 
cytometry analysis. To assess CTL dependent recognition we incubated target cell clones expressing 
the appropriate scQa-1b transgene, Qa-1 deficient bystander cells (Ltk), and the CTL clone D5D2 in 
96 well plates. D5D2 is a Qdm specific CTL clone that is Qa-1b restricted and recognizes endogenous 
Qdm+ (AMAPRTLLL) in L cells.100 After a 4 hour incubation, cells were harvested and assessed via 
flow cytometry. The CTLs (CD8+) and dead cells (CFSE negative) were gated out. Cell killing was 
measured by three readouts: loss of CFSE, reduced forward scatter (FSC), and TO-PRO-3 staining; a 
maker of cell death. D5D2 recognition and killing was dose dependent on the basis of the number of 
effector CTLs incubated with targets and bystanders (figure 4.4A). Lysis of Tg 2L and Tg 26H, was 
comparable to wild-type Qa-1b present on Lg37 cells. Minimal cell death was observed in the Ltk – 
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Ltk treatment (bystander-bystander) showing the assay’s capability of detecting antigen-sepecific 
CTL activity. The CFSE labeling, loss of CFSE, reduced FSC, and TO-PRO-3 positivity are completely 
concordant with one another as demonstrated in Figure 4.5, at a 5:1 effector to target cell ratio 
(E:T).   
Further, to assess the sensitivity of our CFSE killing assay as well as the sensitivity of scQa-1b 
recognition, target cells were incubated with the 524.D11 CTL clone. This CTL clone is Qa-1b 
restricted and dependent on the Qdmk (AMVPRTLL) peptide which is not endogenously present in L 
cells. Therefore, experiments were performed as described above, with the addition of Qdmk 
peptide titrated into the assay at concentrations of 0 nm, 1 nm, 10 nm, and 100 nm. The dose 
response curve observed in this assay (Figure 4.4B) confirmed that both our scQa-1b clones, Tg 2L 
and Tg26H, could be detected with great sensitivity in a peptide dependent manner.   
As a result of its’ high level expression of the mature N-glycosylated form of scQa-1b and the 
observance that CTL recognition mirrored wild-type Qa-1b, Tg 2 was selected for transgenic 
development.    
Transgenic scQa-1b; β2m -/- mouse model development  
To develop the B6-scQa-1b; β2m -/- transgenic line, Tg 2 DNA was purified using a cesium 
chloride gradient. Next, it was linearized and injected into the pronucleus of C57BL/6 (B6) zygotes. 
Transgene positive progeny were identified using PCR and positive offspring were then bred onto 
congenic B6-β2m -/- background. As illustrated in Figure 4.1 this strategy creates a strain where Qa-
1b is the sole MHC I molecule expressed. When B6-scQa-1b; β2m -/-  progency were available we 
analyzed the mice for the presence of peripheral CD8+ T cells and CD8+ thymocytes. To our surprise 
61 
 
flow cytometry experiments demonstrated no CD8+ T cells in the periphery or thymus (data not 
shown).  
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DISCUSSION 
Here we outline the development of a scQa-1b; β2m-/- mouse model to assess the role 
played by the nonclassical MHC Ib molecule Qa-1b in T cell development and function. The design of 
this reductionist system ensures that Qa-1 is the sole MHC I molecule expressed. In in vitro studies 
we determined that the scQa-1b expression vector could be expressed, trafficked to the cell surface, 
and functionally recognized by multiple CTL clones. Two out of three of our designed Tg constructs 
were validated in these assays. Tg 2 was selected for scQa-1b mouse model development since it 
demonstrated strong, consistent expression and CTL recognition that paralleled wild-type Qa-1b. 
Unfortunately, after scQa-1b transgenic development and breeding onto the β2m -/- background, a 
CD8+ T cell phenotype was not observed. CD8+ T cells were not detected in the periphery nor the 
thymus. Consequently, we were unable to study Qa-1 based nonclassical T cell development, the 
potential presence of a Qa-1 restricted “innate-like” cell subset, nor provide greater clarity to the 
role of Qa-1 restricted CD8+ Tregs.  
The inability to translate our in vitro observances into an in vivo system may have been 
caused by a number of factors. The overriding theme is that in an in vivo mouse model there may 
exist genetic or protein regulatory elements, that were absent in transformed L cells. For example, 
the thymic epithelial cells (TECs) and hematopoietic cells (HCs) that mediate T cell selection may 
express Qa-1b not at all, at lower levels, or perhaps only under specific circumstances. Epigenetic 
factors may have also contributed to the absence of our hypothesized phenotype. It is possible that 
during pronuclear injection or breeding that the transgene was localized to a silenced chromosomal 
region. Moreover, it is possible that our engineered construct was silenced as a result of its’ non-
native sequence.     
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Despite this unsuccessful attempt, during this investigation we optimized a non-radioactive 
CFSE based CTL killing assay utilizing flow cytometry. In this assay, target cells and bystander cells 
were labeled at two different CFSE concentrations, 0.42 uM and 5 uM, and together they were 
incubated with a CTL clone. CTL killing was measured by flow cytometry. We used TO-PRO-3 iodide 
as a measure of cell viability, and also observed that cell death correlated with reduced forward 
scatter (FSC) and loss of CFSE staining. On the basis of this finding we suggest that target cells always 
be labeled CFSElow. This ensures that dead bystander cells do not contaminate the CFSElow labeled 
target population. This assay was sensitive enough to display a dose response curve dependent on 
the number of effector CTLs and also the concentration of peptide.  
Historically, the gold standard measure of CTL mediated killing is assessed by a chromium 
(51Cr) release assay. This assay, developed by Brunner and colleagues101, uses the release of the 
radioactive 51Cr isotope into the supernatant as a measure of cell death. This assay has proven to be 
effective, but does have some drawbacks which include the hazard, cost, cumbersome nature of 
radioactivity usage, the difficulties of labeling target cells with 51Cr, and the spontaneous release of 
51Cr that can lead to high background levels. Our CFSE based CTL killing assay, circumvents these 
challenges and provides a much needed update to a classic and useful technique.         
Additionally, using flow cytometry for this assay allows for a multiparametric analysis of 
CD8+ T cells. While not necessary for the studies described here, it is possible to expand on CD8+ T 
cell phenotype by coupling CTL lysis with other markers such as intracellular cytokine levels (i.e. IFN-
γ, IL-17, TNF-α, etc.), upregulated transcription factors (T-bet, Eomes, HELIOS, etc.), and additional 
cell surface molecules (i.e. PD-1, VISTA, CTLA-4, etc).  
We note that in our studies we utilized an immortalized, murine cell line with a restricted 
MHC haplotype. However, recently Mbitikon-Kobo and colleagues also developed a CFSE based 
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killing assay using human PBMCs.102 Intelligently, they selected autologous B cells as the antigen-
presenting target cells and used polyclonal CD8+ T cells. Further, they enriched for the peptide 
specific CD8+ CTLs by incorporating peptide:MHC (pMHC) tetramers. We feel that this was a 
strategically well designed assay, and can be technically improved by incorporating our CFSE labeling 
and E:T incubation methods. Thus creating more clearly labeled target and bystander cell 
populations, while also reducing the overall incubation time of the experiment.    
The study of the role played by nonclassical MHC Ib in T cell development is an emerging 
and overlooked niche of the immune system. Multiple groups have made key insights, suggesting 
these T cells do have important immunological roles, but remain understudied. It is our hope that 
the strategies outlined in our scQa-1b;β2m -/- mouse model can be used by others to study Qa-1, as 
well as the other fifteen murine and eleven human nonclassical MHC Ib molecules. We also hope 
that the numerous advantages outlined by our CFSE, flow cytometry based CTL killing assay can 
replace the 51Cr release assay.   
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FIGURES 
 
 
 
Figure 4.1 Design of the scQa-1b molecule at the genetic and protein level 
 
 
 
 
Figure 4.2 Diagrams of the scQa-1b DNA constructs 
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Figure 4.3 Expression of the scQa-1b molecules as assessed by SDS-PAGE and flow cytometry. 
(A) L (tk-) cells were stably transfected with the following constructs g37 (wild-type Qa-1), Tg 2, 
Tg30, and Tg 26. Clones were isolated via limiting dilution and Qa-1 expression was determined via 
SDS-PAGE. Clone 2L and 26H demonstrated robust expression. A longer exposure can be seen on the 
right and shows wild-type Qa-1 expression (B) Flow cytometry histogram analysis identifies robust 
surface expression on clones 2L and 26H. (C) Quantitated mean fluorescence intensity (MFI) of 
isolated clones presented with the standard error of the mean. 
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